Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma

Burkitt lymphoma (BL) is an aggressive B-cell lymphoma that is associated with poor outcomes in patients with relapsed/refractory disease. This multicenter, retrospective study evaluated real-world CD19 chimeric antigen receptor (CAR) T-cell therapy outcomes in patients with relapsed/refractory BL using data abstracted from the medical records. In total, 31 patients received CAR T cells after a median of 3 previous therapies (range, 1-6). Patients received axicabtagene ciloleucel (n = 19), lisocabtagene maraleucel (n = 4), tisagenlecleucel (n = 4), or other agents (n = 4). Grade 1 to 2 cytokine release syndrome occurred in 83.9% of patients (grade ≥3, 65%), and grade 1 to 2 immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in 29% of patients (grade ≥3, 19.4%). The 28-day mortality rate was 16.1%, including 1 patient who died from grade 5 ICANS. The overall response rate at 1 month was 58.0% with a complete response (CR) rate of 41.9%; however, the 6-month CR rate was only 19.4%. The median progression-free survival was 2.3 months (95% confidence interval, 1.0-9.0), and the median overall survival was 6.0 months (95% confidence interval, 1.9-11.5). Three patients (9.7%) received consolidative allogeneic stem cell transplants, but all subsequently relapsed. In conclusion, CD19 CAR T-cell therapy infrequently delivers long-term disease control in BL. Further investigation is needed to determine the most effective alternative management strategy for these patients.

Authors

Institutions

Publication Details

Journal
Blood
Published
2025-02-12
DOI
https://doi.org/10.1182/blood.2024026831
Citations
14
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
14.64
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma

Jean A. Yared, Manali Kamdar, Vikram Raghunathan, Ajay K. Gopal et al.
14 citations
Blood
CAR-T cell therapy research
14.64
article

Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma

Jean A. Yared, Manali Kamdar, Vikram Raghunathan, Ajay K. Gopal, Michael David Jain, Peter A. Riedell, Ryan C. Lynch, Brian T. Hill, Lori Ann Leslie, Jordan Gauthier, Alan P Skarbnik, Mehdi Hamadani, Ariela Noy, David G. Maloney, Saurabh Dahiya, Frederick Lundry Locke, Ted Gooley, Kikkeri N. Naresh, Roni Shouval, Caron Alyce Jacobson, Brian G. Till, Leyla Shune, Hossein Sadrzadeh, Ashwath Gurumurthi, Alexandre V. Hirayama, Monalisa Ghosh, Valentín Ortiz‐Maldonado, Laura Samples, Paolo Strati, Mazyar Shadman, Christina Poh, Matthew J. Frigault, Mengyang Di, Núria Martínez‐Cibrián, Chaitra S. Ujjani, Narendranath Epperla, Stephen D. Smith, Mehrdad Shakib-Azar
article en
14 citations

Abstract

Burkitt lymphoma (BL) is an aggressive B-cell lymphoma that is associated with poor outcomes in patients with relapsed/refractory disease. This multicenter, retrospective study evaluated real-world CD19 chimeric antigen receptor (CAR) T-cell therapy outcomes in patients with relapsed/refractory BL using data abstracted from the medical records. In total, 31 patients received CAR T cells after a median of 3 previous therapies (range, 1-6). Patients received axicabtagene ciloleucel (n = 19), lisocabtagene maraleucel (n = 4), tisagenlecleucel (n = 4), or other agents (n = 4). Grade 1 to 2 cytokine release syndrome occurred in 83.9% of patients (grade ≥3, 65%), and grade 1 to 2 immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in 29% of patients (grade ≥3, 19.4%). The 28-day mortality rate was 16.1%, including 1 patient who died from grade 5 ICANS. The overall response rate at 1 month was 58.0% with a complete response (CR) rate of 41.9%; however, the 6-month CR rate was only 19.4%. The median progression-free survival was 2.3 months (95% confidence interval, 1.0-9.0), and the median overall survival was 6.0 months (95% confidence interval, 1.9-11.5). Three patients (9.7%) received consolidative allogeneic stem cell transplants, but all subsequently relapsed. In conclusion, CD19 CAR T-cell therapy infrequently delivers long-term disease control in BL. Further investigation is needed to determine the most effective alternative management strategy for these patients.

BloodVol. 145(23)
Boston University (US), University of Maryland, Baltimore (US), Boston Medical Center (US), University of Colorado Hospital (US), Cleveland Clinic (US), Hackensack University Medical Center (US), Seattle Cancer Care Alliance (US), Memorial Sloan Kettering Cancer Center (US), The University of Texas MD Anderson Cancer Center (US), University of Kansas (US), University of Washington (US), Medical College of Wisconsin (US), University of Utah (US), University of Michigan (US), Huntsman Cancer Institute (US), Novant Health (US), Moffitt Cancer Center (US), University of Chicago (US), University of Chicago Medical Center (US), Massachusetts General Hospital (US), Fred Hutch Cancer Center (US), Michigan United (US), Hospital Clínic de Barcelona (ES), Dana-Farber Cancer Institute (US), University of Kansas Medical Center (US), University of Colorado Cancer Center (US), Stanford Medicine (US), Cellular Research (United States) (US), U-M Rogel Cancer Center (US), The Ohio State University (US), University of Colorado Denver (US), Stanford University (US)
Good health and well-being
Openalex Percentile: Top 1%
CAR-T cell therapy research
14.64
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.